Investors

Bioasis Technologies, Inc. is a science-driven company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Our goal is to generate shareholder value by developing and commercializing our proprietary brain delivery technology, xB3, to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.

BTI.V
loading
loading
loading
Today's Open:
loading
Previous Close:
loading
High:
loading
Low:
loading
Volume:
loading

All Public Filings (Canada)

Most Recent Financial Reports (US)

Corporate Presentation

Investor News and Events

  • Feb. 6, 2020 Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that… Read more »

  • Jan. 29, 2020 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 ™?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced it has filed its unaudited… Read more »

  • Bioasis Technologies Inc. Announces Warrant Extension and Repricing

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »

All Events and Presentations